Information Provided By:
Fly News Breaks for January 8, 2020
Jan 8, 2020 | 07:43 EDT
Credit Suisse analyst Matt Miksic raised his price target for NuVasive to $87 from $76 noting that the company has regained its competitive footing and delivered three quarters of improving U.S. Spinal Hardware growth, culminating in 9.5% growth in Q3 in a market growing about 1%-2%. The analyst sees increased adoption of the X360 lateral single-position procedure, as well as pull-through of posterior fixation technologies as driving growth going forward. He reiterates an Outperform rating on the shares.
News For NUVA From the Last 2 Days
There are no results for your query NUVA